Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA 24 FE vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of dysmenorrhea (off-label),Acne vulgaris (off-label)
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Primarily metabolized via CYP3A4. Norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes phase I (hydroxylation via CYP3A4) and phase II (glucuronidation) metabolism.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: ~91% to albumin and SHBG; Ethinyl estradiol: ~97% to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: ~1.5 L/kg; Ethinyl estradiol: ~15 L/kg. Indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Norethindrone: ~64%; Ethinyl estradiol: ~43% (oral).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or acute renal failure due to potential accumulation of components.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with hepatic impairment or active liver disease. No specific dose adjustments provided for mild impairment; use not recommended in Child-Pugh class B or C.
No data available for fictional drug ALYACEN 777.
Safety and efficacy established in females of reproductive age post-menarche. Dosing same as adults (0.10 mg/1.0 mg daily for 24 days, then placebo for 4 days).
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. No specific dose adjustments required for elderly, but consider risks of thromboembolism and other comorbidities.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Hepatic neoplasia,Gallbladder disease,Hypertension,Hyperkalemia in renal impairment (due to drospirenone component in some formulations; not applicable to this product),Glucose intolerance,Depression,Uterine bleeding irregularities,Follicular atresia and amenorrhea after discontinuation,Contact lens intolerance
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal vaginal bleeding,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Hepatic adenoma or carcinoma,Active liver disease with impaired function,Hypersensitivity to any component,Smoking in women over 35
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No food interactions documented. Grapefruit juice may increase estrogen exposure but not clinically significant; no restriction needed.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and potential for neonatal hepatic dysfunction. Contraindicated in pregnancy due to teratogenicity.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in low amounts; M/P ratio not well established. Use during lactation is generally not recommended due to potential adverse effects on infant, including jaundice and hormonal changes. May suppress milk production.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable; use is contraindicated during pregnancy. No dose adjustment can mitigate fetal risk; immediate discontinuation upon confirmed pregnancy is required.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
AUROVELA 24 FE is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate placebo. The iron supplement in placebo pills is not bioavailable and does not treat iron deficiency. Counsel that withdrawal bleed typically occurs during the 4th week (iron pills). Missed pills algorithm: if one active pill missed, take as soon as remembered; if two or more missed, take last missed and use backup contraception for 7 days. Induction of CYP3A4 by rifampin, anticonvulsants, St. John's wort may reduce efficacy. Do not prescribe with concomitant hepatitis C therapy containing ombitasvir/paritaprevir/ritonavir due to ALT elevations.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, preferably after the evening meal to reduce nausea.,The last 7 tablets are brown iron pills; you will have a withdrawal bleed during this time.,If you vomit within 4 hours of taking an active pill, take another active pill from a separate pack.,Missing two or more active pills may require backup contraception (condoms) for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking while on this medication.,Report any symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature away from moisture and heat.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA 24 FE vs ALYACEN 777, answered by our medical review team.
AUROVELA 24 FE is a Oral Contraceptive that works by Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA 24 FE and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA 24 FE is: One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA 24 FE and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA 24 FE is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and poten. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.